News
Have we stopped asking questions? Mandatory Vaccination under the spotlight at Canberra event
1+ hour, 16+ min ago (1151+ words) Prior to 2021, most Australians likely felt little reason to delve into how vaccines available in Australia are developed, tested, approved and rolled out. Nor had regulatory agencies like the Therapeutic Goods Administration (TGA) and the Australian Technical Advisory Group on…...
Why the world is still searching for HIV vaccine: Progress, challenges and new hope
4+ hour, 37+ min ago (79+ words) The Eastleigh Voice Why the world is still searching for HIV vaccine: Progress, challenges and new hope Despite major advances in treatment and prevention, scientists continue to face scientific hurdles in developing a vaccine, even as new technologies like m…...
Astra Zeneca Gets FDA Nod for New Hypertension Drug Baxfendy
14+ hour, 21+ min ago (536+ words) Astra Zeneca'AZN announced that the FDA has approved baxdrostat for treating adult patients with uncontrolled or treatment-resistant hypertension as an add-on to other antihypertensive drugs. Baxdrostat, a first-in-class aldosterone synthase inhibitor (ASI), will be marketed as Baxfendy. Following the nod,…...
Khondrion Announces First Patient Dosed in Phase II Study Targeting Debilitating Post-COVID Fatigue
1+ hour, 50+ min ago (488+ words) Carroll County Mirror-Democrat NIJMEGEN, The Netherlands, May 19, 2026 (GLOBE NEWSWIRE) -- Khondrion today announced that the first patient has been dosed in the Phase II SON4 PEM study (NCT07298005), a key clinical milestone in the development of sonlicromanol beyond primary mitochondrial disease. Sonlicromanol is…...
Telix completes enrollment in glioblastoma therapy trial By Investing. com
9+ hour, 54+ min ago (207+ words) Updated May 18, 2026 22: 06 The company stated that no dose-limiting toxicities have been observed to date, including at the maximum administered dose of 10 GBq total activity, according to a press release statement. IPAX-2 is a Phase 1 dose-finding study evaluating the safety and…...
Parents of children with Duchenne disease to meet with Patriarch Shio III
11+ hour, 21+ min ago (428+ words) Parents of children with Duchenne disease will meet with the Catholicos-Patriarch of All Georgia, Shio III. Tako Gogoladze, the mother of one of the children, said that a call was received from the Patriarchate, and the families were informed that Catholicos-Patriarch…...
Perth hosts Aus Medtech conference as industry focuses on innovation and commercialisation - Biotech
8+ hour, 2+ min ago (274+ words) Leaders from Australia's medical technology sector have gathered in Perth for Aus Medtech 2026 to explore innovation, translation and commercialisation across the medtech ecosystem. Australia's medtech industry, which includes more than 900 companies, is being cast as a critical driver of growth…...
United States Ig A Nephropathy Treatment Market (2026-2033) | How Are Clinical Trials Advancing Innovation in Ig A Nephropathy Drug Development (2026)?
1+ hour, 23+ min ago (84+ words) United States Ig A Nephropathy Treatment Market (2026-2033) | open PR. com United States Ig A Nephropathy Treatment Market (2026-2033) | How Are Clinical Trials Advancing Innovation in Ig A Nephropathy Drug Development (2026)? Press release from: Data M Intelligence 4 Market Research LLP Ig A…...
GOSS: Seralutinib showed significant vascular benefits in PAH, with a major debt reduction plan underway
19+ hour, 53+ min ago (75+ words) Trading View GOSS: Seralutinib showed significant vascular benefits in PAH, with a major debt reduction plan underway FDA meeting set for June to discuss seralutinib's regulatory path, with NDA submission targeted for September 2026. PROSERA substudy showed significant multi-compartment vascular improvements,…...
Aardvark's Clinical Hold Isn't Bad Luck " It's a Pre-Clinical Characterization Failure
59+ min ago (969+ words) The Clinical Trial Vanguard Aardvark's Clinical Hold Isn't Bad Luck " It's a Pre-Clinical Characterization Failure On February 27, 2026, a healthy volunteer enrolled in a study of ARD-101 " Aardvark Therapeutics' small-molecule candidate for Prader-Willi syndrome " developed a reversible cardiac abnormality. Aardvark voluntarily…...